Clinical trial results for
previously treated
head and neck
squamous cell cancer
For adults with squamous cell carcinoma of the head and neck (SCCHN) that has returned or spread after previous treatment
Clinical trial results for
previously treated
head and neck
squamous cell cancer
For adults with squamous cell carcinoma of the head and neck (SCCHN) that has returned or spread after previous treatment
Actor portrayals.
In a clinical trial of 361 people with previously treated squamous cell carcinoma of the head and neck (SCCHN) that had returned or spread, 240 people were given OPDIVO and 121 people were given standard therapy options that included cetuximab, methotrexate, or docetaxel.
Half the people were alive
Half the people were alive
In the clinical trial, people given OPDIVO had a 30% lower risk of dying than those given standard therapy options that included cetuximab, methotrexate, or docetaxel.
OPDIVO will not work for everyone. Individual results may vary.
Terry’s cancer kept returning with radiation and a platinum-based therapy. Learn more about his treatment journey with OPDIVO for his previously treated squamous cell carcinoma of the head and neck (SCCHN).
See your recommended treatment plan and what to expect from an infusion
For people with previously treated squamous cell carcinoma of the head and neck
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with head and neck cancer (squamous cell carcinoma) that has come back or spread and you have tried chemotherapy that contains platinum and it did not work or is no longer working.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.